摘要
目的:研究白蛋白紫杉醇联合顺铂对非小细胞肺癌(NSCLC)患者T细胞亚群及血清肿瘤标志物水平的影响。方法:本研究为随机对照研究,选取2022年2月至2023年2月南阳张仲景医院肿瘤内科收治的194例NSCLC患者为研究对象,男134例,女60例,年龄(62.37±7.19)岁,年龄范围为45~80岁,采用随机数表法分组,即利用EXCEL函数获取随机数194个,依据入院时间顺序依次分配,奇数设为紫杉醇组( n=97),偶数设为白蛋白紫杉醇组( n=97)。紫杉醇组采用紫杉醇联合顺铂治疗,白蛋白紫杉醇组采用白蛋白紫杉醇联合顺铂治疗。比较两组患者临床治疗效果、T细胞亚群[CD3^(+)T淋巴细胞(CD3^(+))、CD4^(+)T淋巴细胞(CD4^(+))、CD4^(+)/CD8^(+)T淋巴细胞(CD8 +)]、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原]、生存质量[癌症治疗功能评价系统(FACT-L)量表]、体能状态(卡式评分)及不良反应发生情况。 结果:白蛋白紫杉醇组临床疾病控制率[74.2%(72/97)]高于紫杉醇组[59.8%(58/97)],差异有统计学意义( P<0.05)。治疗2个周期后,白蛋白紫杉醇组患者CD3 +[(51.65±4.16)%]、CD4 +[(27.56±3.57)%]、CD4^(+)/CD8^(+)(1.21±0.35)水平高于紫杉醇组[(48.17±3.86)%、(24.28±3.39)%、(1.01±0.32)];白蛋白紫杉醇组CYFRA21-1[(3.41±1.04)U/ml]、CA125[(47.59±8.34)U/ml]、癌胚抗原[(38.71±7.95)μg/L]低于紫杉醇组[(4.36±1.31)U/ml、(55.28±8.69)U/ml、(45.32±8.47)μg/L];白蛋白紫杉醇组患者卡式评分[(82.58±6.12)分]高于紫杉醇组[(75.48±5.71)分]、FACT-L评分[(43.98±12.59)分]低于紫杉醇组[(54.87±11.26)分],差异有统计学意义( P<0.05)。白蛋白紫杉醇组不良反应发生率[73.2%(71/97)]低于紫杉醇组[88.7%(86/97)],差异有统计学意义( P<0.05)。 结论:NSCLC患者采用白蛋白紫杉醇联合顺铂治疗,可降低肿瘤标志物水平,有效控制病情进展,还可保护机体免疫功能,改善患者体能状态及生存质量,�
ObjectiveTo investigate the effects of albumin-paclitaxel combined with cisplatin on T cell subsets and serum tumor markers in patients with non-small cell lung cancer(NSCLC).MethodsThis study was a randomized controlled study,a total of 194 patients with NSCLC who received in the Oncology Department of the Zhang Zhongjing Hospital from February 2022 to February 2023,including 134 males and 60 females,aged(62.37±7.19)years old,ranging from 45 to 80 years old,grouped by random number table method,in other words,EXCEL function was used to obtain 194 random numbers,which were successively allocated according to the order of admission time,odd numbers were set as paclitaxel group(n=97),and even numbers as albumin paclitaxel group(n=97).The paclitaxel group was treated with paclitaxel combined with cisplatin,and the albumin paclitaxel group was treated with albumin paclitaxel combined with cisplatin.The clinical therapeutic effect,T cell subsets[cluster of differentation 3(CD3^(+)),cluster of differentation 4(CD4^(+)),CD4^(+)/cluster of differentation 8(CD8^(+))],tumor markers[cytokeratin19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen],quality of life[functional assessment of cancer therapy-L(FACT-L)scales],physical status(card score)and occurrence of adverse reactions of the two groups were compared.ResultsThe clinical disease control rate of albumin paclitaxel group[74.2%(72/97)]was higher than that of paclitaxel group[59.8%(58/97)],the difference was statistically significant(P<0.05).After 2 cycles of treatment,the levels of CD3^(+)[(51.65±4.16)%],CD4^(+)[(27.56±3.57)%],CD4^(+)/CD8^(+)(1.21±0.35)in albumin paclitaxel group were higher than those in paclitaxel group[(48.17±3.86)%,(24.28±3.39)%,(1.01±0.32)],CYFRA21-1[(3.41±1.04)U/ml],CA125[(47.59±8.34)U/ml]and carcinoembryonic antigen[(38.71±7.95)μg/L]in albumin paclitaxel group were lower than those in paclitaxel group[(4.36±1.31)U/ml,(55.28±8.69)U/ml,(45.32±8.47)μg/L];The card score[(82.58±6.12)points]in
作者
高红果
魏娜
朱红梅
Gao Hongguo;Wei Na;Zhu Hongmei(Department of Oncology,Zhang Zhongjing Hospital,Nanyang 473000,China)
出处
《中国临床实用医学》
2023年第5期22-27,共6页
China Clinical Practical Medicine
基金
河南省医学科技攻关计划(联合共建)项目(LHGJ20217021)
关键词
白蛋白紫杉醇
顺铂
非小细胞肺癌
T细胞亚群
Albumin paclitaxel
Cisplatin
Non-small cell lung cancer
T cell subpopulation
